[Fellow Investor Talks About Hot Topics] The U.S. Will Waive Intellectual Property Patents for COVID-19 Vaccines—Are You Still Bullish on the Pandemic-Themed Concept?

As the pandemic continues to surge overseas and vaccine shortages tighten, local time...5Moon5On [date], the United States announced its support for waiving intellectual property protections for COVID-19 vaccines. The Biden administration, local time...5Moon5On the same day, a decision was announced stating that the United States will waive intellectual property patents for COVID-19 vaccines. U.S. Trade Representative Katherine Tai.5The U.S. government announced this decision in a statement.

Market impact

Following the news, global vaccine stocks plummeted. In the U.S. stock market,ModernaDown over6%Novavax Pharmaceuticals fell by nearly...5%，BioNTechDown over3%; Regarding Hong Kong stocks, Fosun PharmaHThe stock fell by more than [a certain percentage] in early trading.22%CanSino Biologics once fell by more than...19%; As of today’s closing priceFosun PharmaHStock decline14.13%; CanSino Biologics' decline15.01%; Kexing Pharma's decline8.43%; Decline in Chinese biopharmaceutical stocks5.83%。

Fellow investors are all paying attention.

As soon as the news broke that the U.S. would grant a patent waiver for COVID-19 vaccines, global vaccine stocks plummeted—once upon a time...“Hot commodity”Are pandemic-related stocks still worth holding? Fellow investors share their views. As for the future performance of pandemic-related stocks, those who are bullish and those who are bearish remain evenly matched, each holding around 50%.

The fellow investor community is still closely following the developments of the incident, and many fellow investors have raised questions about whether this initiative will actually be implemented.

Now, Hot Girl will take you to check out the exciting insights from fellow investors!

@YJ炸鸡哥：How difficult is it to open up a patent?

It seems that unanimous consent from all 164 WTO members is required for it to succeed. This issue is too complicated. It’s not enough to simply open up patents in order to manufacture—except for the patents on COVID-19 vaccines. There are still far too many technological barriers. Would those countries really just hand over all their technologies—technologies their own companies have spent years and billions of dollars researching—to others so easily? Right now, only India and South Africa are pushing for patent openness; the EU countries won’t so readily give up their investments and let Indians copy their products. And who’s going to oversee the safety of the vaccines? India is so fond of copying and counterfeiting that everyone’s jumping on the bandwagon. Who exactly is the real vaccine and who is the fake one?

@ywwww:The Five Obstacles to Patent Exemptions

1. The entire incident was discussed within the framework of the WTO. In reality, the WTO’s efficiency in getting things done—and the time it takes—pales in comparison to that of the neighborhood street office right next to your home... much less efficient.

2. The inheritance relationship regarding intellectual property exemptions and technology transfer.

3. The exemption applies not only to mRNA vaccines but to all COVID-19 vaccines (though, of course, at this point, only mRNA vaccines seem worthy of being exempted).

4. The time required for negotiation exemptions, as well as changes in the epidemic situation and global vaccine supply during this period.

5. Finally, if intellectual property rights are truly abandoned, subsidies to pharmaceutical companies will also be eliminated.

@16908276 ：Human life always takes precedence over commercial value.

Waiving the intellectual property patents for COVID-19 vaccines is an act that benefits all of humanity. While this may put pressure on the stock prices of companies involved in vaccine research and development, human lives are always more valuable than commercial interests.

@laurentyeung ：Balancing Small Economic Accounts with Big Economic Accounts

It’s not enough to focus solely on the small economic benefits of the vaccine itself; we must also consider the larger economic benefits—particularly for developing countries and the global economy as a whole—that will arise once vaccine patents are waived and the global economy begins to rebound, benefiting the U.S. and developed nations. Regardless of how the specific implementation ultimately unfolds, this move will undoubtedly help accelerate the world economy’s return to normalcy.

@17126431：mRNAThe prospects of technology are highlighted.

️As a global public health event, it is entirely reasonable and lawful for countries to directly produce emergency medicines without requiring authorization—this aligns with the original intent of intellectual property rights! It’s not impossible that the U.S. might be behind this.showPander to the world.
mRNAThe key lies in production.know howNot covered by basic-level patents, but many manufacturers are also not based in the U.S.
In the long run, this will certainly be beneficial to the development of this patent in other diseases, such as cancer treatments and therapies. This global public event has demonstrated that.mRNAThe safety of the technology and its immeasurable potential.

@球球姐：Beneath the risks lie abundant opportunities.

First, he didn’t specify which generation of vaccine was being abandoned. As far as I recall, there’s already been one mutation in the U.S., one in the U.K., and one in India. It’s still uncertain whether the so-called “abandoned” vaccines can even cure the current virus. So why abandon them in the first place? Isn’t it just to kickstart the economy? People will only go out and work once they feel there’s hope—without anyone working, who’s going to produce the vaccines? Besides, their country requires Q&M Dental vaccinations for everyone. With such massive, mandatory demand, could a single or just a couple of companies possibly handle it all? Right now, the prices of these stocks are basically at rock-bottom levels. From masks and virus tests to prevention measures and medical institutions—all of these will inevitably come with a price tag. By the time they start selling globally under the banner of the EU, will you still be able to afford them?

Note: The above insightful perspectives were selected based on a comprehensive assessment of both content views and engagement levels.To ensure smooth reading, we’ve made minor edits to some fellow investor comments without altering the original text’s viewpoints. If you have any objections, feel free to contact Today’s Hot Feedback at any time.

The fellow investors selected as above will receive 188 points as a reward for "Outstanding Hot Comments." We welcome more fellow investors to pay attention to trending topics in the community, participate, and share your insightful perspectives!

626K Views